Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson’s Disease
作者:Tommi P. Kilpeläinen、Henri T. Pätsi、Reinis Svarcbahs、Ulrika H. Julku、Tony S. Eteläinen、Hengjing Cui、Samuli Auno、Nina Sipari、Susanna Norrbacka、Teppo O. Leino、Maria Jäntti、Timo T. Myöhänen、Erik A. A. Wallén
DOI:10.1021/acs.jmedchem.3c00235
日期:2023.6.8
reducing α-synuclein (αSyn) dimerization and enhancing protein phosphatase 2A activity in a concentration–response manner, as well as reducing reactive oxygen species production. From the best performing oxazoles, HUP-55 was selected for in vivo studies. Its brain penetration was evaluated, and it was tested in αSyn virus vector-based and αSyn transgenic mouse models of Parkinson’s disease, where it
脯氨酰寡肽酶(PREP)是人体内广泛分布的丝氨酸蛋白酶,可裂解含脯氨酸的肽;然而,最近的研究表明,它对神经退行性病变致病过程的影响源自直接的蛋白质-蛋白质相互作用(PPI),而不是来自其对某些神经肽水平的调节。我们发现了新型非肽类恶唑类 PREP 抑制剂,它偏离了 PREP 抑制剂已知的构效关系。这些新化合物是 PREP 的 PPI 的有效调节剂,以浓度响应方式减少 α-突触核蛋白 (αSyn) 二聚化并增强蛋白磷酸酶 2A 活性,并减少活性氧的产生。从性能最好的恶唑中,选择HUP-55进行体内研究学习。我们评估了它的大脑渗透性,并在基于 αSyn 病毒载体和帕金森病 αSyn 转基因小鼠模型中进行了测试,它恢复了运动障碍并降低了纹状体和黑质中寡聚 αSyn 的水平。